Alkermes (NASDAQ:ALKS) Updates FY 2025 Earnings Guidance

Alkermes (NASDAQ:ALKS) updated its FY 2025 earnings guidance on Wednesday. The company provided EPS guidance of 1.030-1.210 for the period, compared to the consensus EPS estimate of 1.740. The company issued revenue guidance of $1.3 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. HC Wainwright restated a “neutral” rating and issued a $46.00 price target on shares of Alkermes in a report on Thursday. Piper Sandler reaffirmed an “overweight” rating and issued a $37.00 target price (down from $38.00) on shares of Alkermes in a research report on Friday, October 25th. Stifel Nicolaus raised Alkermes from a “hold” rating to a “buy” rating and raised their price target for the company from $25.00 to $36.00 in a report on Tuesday, November 5th. Cantor Fitzgerald decreased their target price on Alkermes from $48.00 to $43.00 and set an “overweight” rating for the company in a research note on Friday, October 25th. Finally, Mizuho increased their price target on Alkermes from $35.00 to $40.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $37.25.

Alkermes Trading Up 0.1 %

NASDAQ:ALKS traded up $0.04 on Friday, reaching $36.04. The company’s stock had a trading volume of 73,198 shares, compared to its average volume of 1,645,947. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.03 and a current ratio of 3.45. The firm has a market cap of $5.83 billion, a PE ratio of 18.46, a PEG ratio of 1.83 and a beta of 0.49. The business’s 50-day moving average price is $30.31 and its two-hundred day moving average price is $28.73. Alkermes has a 1-year low of $22.90 and a 1-year high of $36.14.

Alkermes (NASDAQ:ALKS) last posted its quarterly earnings results on Wednesday, February 12th. The company reported $0.92 earnings per share for the quarter, beating analysts’ consensus estimates of $0.81 by $0.11. Alkermes had a return on equity of 24.92% and a net margin of 22.15%. Equities research analysts anticipate that Alkermes will post 2.23 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Craig C. Hopkinson sold 61,151 shares of the business’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $32.07, for a total value of $1,961,112.57. Following the transaction, the executive vice president now directly owns 47,576 shares of the company’s stock, valued at $1,525,762.32. The trade was a 56.24 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Christian Todd Nichols sold 5,208 shares of the business’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $29.15, for a total value of $151,813.20. Following the completion of the transaction, the senior vice president now directly owns 60,703 shares in the company, valued at $1,769,492.45. This represents a 7.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 179,189 shares of company stock worth $5,723,518 in the last 90 days. Company insiders own 4.89% of the company’s stock.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.